Brillanti Stefano
Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
J Clin Med. 2022 Mar 13;11(6):1587. doi: 10.3390/jcm11061587.
In 1977 the viral Delta agent was discovered and subsequently characterized as the hepatitis Delta virus (HDV). HDV infection is associated with HBV infection since the defective HDV needs HBV to infect and replicate in the liver. Even if not a frequent cause of chronic liver disease, HDV infection is responsible for an aggressive progression of hepatitis towards advanced liver disease. At present, no FDA approved treatment exists for this specific form of hepatitis. Interferon alfa has been recommended as off-label therapy by major scientific societies (AASLD, EASL and APASL) and has proved effective in about one quarter of patients. In recent years, new therapeutic approaches have been studied, and EMA has approved a new drug (bulevirtide) for Delta hepatitis. In this review, we encompass the 45-year journey of managing Delta hepatitis and address the most recent developments in treating this severe and aggressive liver disease.
1977年，病毒δ因子被发现，随后被鉴定为丁型肝炎病毒（HDV）。HDV感染与HBV感染相关，因为缺陷型HDV需要HBV才能在肝脏中感染和复制。即使HDV感染并非慢性肝病的常见病因，但它会导致肝炎迅速进展为晚期肝病。目前，美国食品药品监督管理局（FDA）尚未批准针对这种特殊形式肝炎的治疗方法。主要科学协会（美国肝病研究学会、欧洲肝脏研究学会和亚太肝脏研究学会）已推荐干扰素α作为标签外治疗方法，并且已证明该方法对约四分之一的患者有效。近年来，人们研究了新的治疗方法，欧洲药品管理局（EMA）已批准一种新药（布立伏定）用于治疗丁型肝炎。在本综述中，我们涵盖了管理丁型肝炎的45年历程，并阐述了治疗这种严重且进展迅速的肝病的最新进展。
